http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Yuri Cho ),( Jeong Hoon Lee ),( Dong Hyeon Lee ),( Min Jong Lee ),( Jeong Ju Yoo ),( Won Mook Choi ),( Young Youn Cho ),( Yun Bin Lee ),( Eun Ju Cho ),( Su Jong Yu ),( Nam Joon Yi ),( Kwang Woong Le 대한간학회 2013 춘·추계 학술대회 (KASL) Vol.2013 No.1
Background/aims: Some patients with hepatocellular carcinoma (HCC) beyond the Milan criteria (MC) have favorable tumor biology, and that these patients would have low risk of tumor recurrence after living donor liver transplantation (LDLT). This study was designed to develop a model of tumor recurrence after LDLT for HCC beyond the MC, so as to select the best candidates for LDLT in HCC beyond the MC. Methods: Consecutive patients who had undergone LDLT beyond the MC at Seoul National University Hospital between September 2001 and January 2013 were analyzed. Demographic, clinical, and tumor characteristics were evaluated and a model to predict recurrence after LDLT (MoRAL score) was created. Results: A total of 104 patients were included. The median follow-up was 52.7 (range, 1.6-157.5) months. Their 5-year overall survival and cumulative recurrence rates were 70.4% and 41.8%, respectively. In multivariate analysis, independent pretransplant risk factors for HCC recurrence were serum AFP (OR=1.003, P=0.013) and PIVKA-II (OR=1.001, P=0.050) levels. AFP reflected maximal tumor size and PIVKA-II reflected tumor number and type (nodular or diffuse/infiltrative) (all P<0.001). Using Cox proportional hazards model, MoRAL score ( )was derived (median, 108.3; range 33.7-3928.3). The concordance statistic of MoRAL (0.836) was superior to CLIP score (0.772), TNM stage (0.600), JIS stage (0.601) and T classification (0.626). The tumor recurrence after LDLT was significantly related to mortality (OR=21.6, P<0.001). Conclusions: A new model to predict tumor recurrence of HCC patients beyond the MC after LDLT based on objective parameters provides refined prognostication (Figure 1). External validation is warranted.
Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-regulating Galectin-14
( Hyeki Cho ),( Yun Bin Lee ),( Yuri Cho ),( Jeong-hoon Lee ),( Dong Hyeon Lee ),( Jeong-ju Yoo ),( Young Youn Cho ),( Eun Ju Cho ),( Su Jong Yu ),( Yoon Jun Kim ),( Jong In Kim ),( Jong Hun Im ),( Ju 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: Aptamers are small synthetic oligonucleotides that bind to target proteins with high specificity and affinity. AS1411 is an aptamer that binds to the protein nucleolin, which is overexpressed in the cytoplasm and occurs on the surface of cancer cells. We investigated the therapeutic potential of aptamers in treating hepatocellular carcinoma (HCC) by evaluating anti-tumor effects and confirming the affinity and specificity of AS1411 and modified AS1411 aptamers in HCC cells. Methods: Cell growth was assessed using the MTS assay, and cell death signaling was explored by immunoblot analysis. Fluore- scence-activated cell sorting was performed to evaluate the affinity and specificity of AS1411 aptamers in SNU-761 HCC cells. We investigated the in vivo effects of the AS1411 aptamer using BALB/c nude mice in a subcutaneous xenograft model with SNU-761 cells. Results: Treatment with a modified AS1411 aptamer significantly decreased in vitro (under normoxic [P=0.035] and hypoxic [P=0.018] conditions) and in vivo (under normoxic conditions, P=0.041) HCC cell proliferation compared to control aptamers. AS1411 and control aptamers failed to control HCC cell proliferation. However, AS1411 and the modified AS1411 aptamer did not induce caspase activation. Decrease in cell growth by AS1411 or modified AS1411 was not prevented by caspase or necrosis inhibitors. In a microarray, AS1411 significantly enhanced galectin-14 expression. Suppression of HCC cell proliferation by the modified AS1411 aptamer was attenuated by galectin-14 siRNA transfection. Conclusions: The modified AS1411 aptamer suppressed HCC cell growth in vitro and in vivo by up-regulating galectin-14 expression. Modified AS1411 aptamers may have therapeutic potential as a novel targeted therapy for HCC.
Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma
Yuri Cho,Bo Hyun Kim,Joong-Won Park 대한간학회 2023 Clinical and Molecular Hepatology(대한간학회지) Vol.29 No.-
The incidence of hepatocellular carcinoma (HCC) associated with nonalcoholic fatty liver disease (NAFLD) has been increasing worldwide, including Asia. Most patients with NAFLD-related HCC are at a much-advanced stage and older age at the time of diagnosis than those with virus-related HCC because they have not undergone HCC surveillance. This review provides an overview of the mechanism of hepatocarcinogenesis in NAFLD, preventive strategies for NAFLD-related HCC, and strategies for the surveillance of patients with NAFLD.
Yuri Cho,Bo Hyun Kim,Joong-Won Park 대한간학회 2023 Clinical and Molecular Hepatology(대한간학회지) Vol.29 No.2
Hepatocellular carcinoma (HCC) is highly prevalent and the third most common cause of cancer-related death in Asia. In contrast to the West, the main etiology of HCC in many Asian countries except Japan is chronic hepatitis B virus infection. Differences in the major causes of HCC lead to significant clinical and treatment differences. This review summarizes and compares guidelines on managing HCC from China, Hong Kong, Taiwan, Japan, and South Korea. From oncology and socio-economic perspectives, factors such as underlying diseases, staging methods, government policies, insurance coverage, and medical resources contribute to varying treatment strategies among countries. Furthermore, the differences in each guideline are fundamentally caused by the lack of incontrovertible medical evidence, and even existing results of clinical trials can be interpreted differently. This review will provide a complete overview of the current Asian guidelines for HCC in recommendations and in practice.
Yuri Cho,Giau Thi Nguyen,Quang Van Duong,Seung Tae Choi 대한기계학회 2022 JOURNAL OF MECHANICAL SCIENCE AND TECHNOLOGY Vol.36 No.7
In this study, resistive-type stretch sensors based on embroidered conductive threads were investigated to determine the best combinations of various conductive threads and fabrics, as well as the ideal embroidery patterns and their optimal geometric parameters. Among various conductive threads, a silver-plated nylon fiber of 280 denier was selected as the best conductive thread, because it featured the highest gauge factor and excellent stretchability and reliability. Among the various tested fabrics, the poly fine brushed knit fabric could endure high repetitive stretching without any permanent deformation, thus guaranteeing an apparent electrical resistance-strain curve. Zigzag, couching, overcasting, and decorative patterns were embroidered on this poly fine brushed knit fabric using the 280 denier silver-plated nylon fiber. The electrical resistance curves of the embroidered conductive threads were measured as functions of the applied strain and frequency. The zigzag pattern exhibited the best resistancestrain response and the highest gauge factor. The electrical resistance-strain curve was also measured through a cyclic loading test involving 100000 cycles. Results indicated that the hysteresis behavior and drift in electrical resistance may have hindered accurate measurements of the strain during the stretching and releasing process, which needs to be corrected by using a compensation algorithm. To demonstrate the proposed stretch sensor, knee motions were monitored using a resistive-type stretch sensor implemented on athletic cloth.
Age-Related Effects of Sodium Arsenite on Splenocyte Proliferation and Th1/Th2 Cytokine Production
Yuri Cho,김대경,Kyong Hoon Ahn,백문정,최종민,Jung Eun Ji,Jong Hoon Won,Zhicheng Fu,Ji Min Jang 대한약학회 2012 Archives of Pharmacal Research Vol.35 No.2
Aging is associated with immune dysfunction and conditions such as inflamm-aging and immunosuppression. Arsenic, an environmental contaminant distributed worldwide, affects the immune system. This study tested the hypothesis that arsenic has distinct effects on T cell proliferation and the production of cytokines by activated T cells. Murine splenocytes from young (2 months) and aged (24-26 months) C57BL/6 mice were exposed to arsenite (As3+), the most toxic form of inorganic arsenic, and stimulated with concanavalin A (Con A) or anti-CD3 antibody. T cell proliferation decreased significantly in response to Con A and anti-CD3 at subtoxic doses of arsenite in splenocytes from both young and aged mice. Arsenite, added concurrently with Con A or anti-CD3, significantly inhibited the production of interleukin-2 (IL-2), interferon-γ (IFN-γ), and interleukin-4 (IL-4) by splenocytes from young mice and significantly reduced the production of IL-10 by splenocytes from aged mice. In contrast, the production of IL-2 and IL-4 by splenocytes from aged mice was only slightly affected by arsenite. The results show that arsenic exposure reduces the immune response in splenocytes. Moreover,this effect may be influenced by aging.
( Yuri Cho ),( Eun Ju Cho ),( Jeong Hoon Lee ),( Su Jong Yu ),( Jung Hwan Yoon ),( Yoon Jun Kim ) 대한간학회 2015 Clinical and Molecular Hepatology(대한간학회지) Vol.21 No.4
Background/Aims: The previous standard treatment for chronic hepatitis C (CHC) patients, comprising a combination of pegylated interferon (IFN) and ribavirin, was associated with suboptimal efficacy and severe adverse reactions. A new era of direct-acting antivirals is now dawning in Korea. Early experience of applying sofosbuvir-based therapy to CHC patients in Korea is reported herein. Methods: Data on efficacy and safety were collected for CHC patients treated with a combination of sofosbuvir plus ribavirin or sofosbuvir/ledipasvir with or without ribavirin. Results: This retrospective study included 25 consecutive patients who received sofosbuvir-based therapy (19 with genotype 1b and 6 with genotype 2) at Seoul National University Hospital from May 2014 to April 2015. A virologic response was achieved at week 4 by 85.7% and 80% of the patients with genotypes 1b and 2, respectively. The HCV-RNA level decreased more slowly in IFN-experienced than in treatment-naive patients with genotype 1b. However, the sustained virologic response at week 12 (SVR12) rate did not differ among these patients, and was as high as 100%. The presence of cirrhosis significantly increased the risk of a virologic response failure at week 4 (OR, 11.0; P=0.011) among patients with HCV genotype 1b. Only five patients (20%) experienced minor adverse events, including grade 1 fatigue and headache. The hemoglobin level decreased slightly after sofosbuvir-based therapy, but there was no case of premature discontinuation of this therapy. Conclusions: In a real clinical practice, sofosbuvir-based therapy for CHC patients in Korea achieved optimal antiviral efficacy with insignificant adverse events. Long-term follow-up data are warranted to ensure the sustained antiviral efficacy and long-term safety of sofosbuvir-based IFN-free therapy. (Clin Mol Hepatol 2015;21:358-364)